Study of GLP-1 Agonist Effects on Reproductive Hormones and Metabolism in Obese Adolescent Girls with PCOS

What this Trial Is About

This research aims to investigate how a GLP-1 receptor agonist affects neuro-reproductive function in obese adolescent females with Polycystic Ovary Syndrome PCOS. PCOS is a common hormonal disorder affecting females of reproductive age, often linked to obesity and disrupted hormone rhythms. The study focuses on how the GLP-1 hormone, which influences insulin and reproductive hormone release, may impact these neuroendocrine rhythms and metabolism in this group. The study involves up to 20 female adolescents aged 12 to 18 years, who are at least two years post-menarche, have obesity BMI at or above the 95th percentile, and diagnosed PCOS by NIH criteria. Participants will receive weekly subcutaneous injections of the GLP-1 receptor agonist Semaglutide, alongside lifestyle advice on diet and exercise. Treatment will be titrated to the maximal dose and continue for 16 weeks. Participants will be evaluated before and after treatment with blood tests measuring hormone levels such as LH, FSH, testosterone, estradiol, and progesterone. Body composition will be assessed using dual x-ray absorptiometry DXA scans. Carbohydrate metabolism and insulin sensitivity will be analyzed using fasting glucose and insulin levels. The study aims to observe changes in hormone pulse frequency and amplitude, body fat, and metabolism over the 16-week period.

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)